{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:12:24Z","timestamp":1775567544106,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":819,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.5604\/16652681.1231577","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T11:18:30Z","timestamp":1487848710000},"page":"188-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Mohammad Saeid","family":"Rezaee-Zavareh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khashayar","family":"Hesamizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Behnava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Gholami-Fesharaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidar","family":"Sharafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 Suppl.","key":"10.5604\/16652681.1231577_bib0005","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatology"},{"key":"10.5604\/16652681.1231577_bib0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"The Lancet"},{"key":"10.5604\/16652681.1231577_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1231577_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","year":"2015","journal-title":"J Hepatology"},{"key":"10.5604\/16652681.1231577_bib0025","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New Engl J Med"},{"key":"10.5604\/16652681.1231577_bib0030","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"New Engl J Med"},{"key":"10.5604\/16652681.1231577_bib0035","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New Engl J Med"},{"key":"10.5604\/16652681.1231577_bib0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-230X-9-89","article-title":"What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?","volume":"9","author":"Tarantino","year":"2009","journal-title":"BMC Gastroen-terology"},{"key":"10.5604\/16652681.1231577_bib0045","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS medicine"},{"key":"10.5604\/16652681.1231577_bib0050","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration","year":"2008"},{"key":"10.5604\/16652681.1231577_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jspi.2004.01.005","article-title":"One-sided confidence intervals in discrete distributions","volume":"131","author":"Cai","year":"2005","journal-title":"Journal of Statistical Planning and Inference"},{"key":"10.5604\/16652681.1231577_bib0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.5604\/16652681.1231577_bib0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledi-pasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1231577_bib0070","series-title":"Once daily ledipasvir\/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection","author":"Stedman","year":"2015"},{"key":"10.5604\/16652681.1231577_bib0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.5604\/16652681.1231577_bib0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3748\/wjg.v17.i4.419","article-title":"Peginterferon and rib-avirin treatment for hepatitis C virus infection","volume":"17","author":"Tsubota","year":"2011","journal-title":"World J Gas-troenterol"},{"key":"10.5604\/16652681.1231577_bib0085","first-page":"154","article-title":"Direct-acting antiviral medications for chronic hepatitis C virus infection","volume":"7","author":"Jazwinski","year":"2011","journal-title":"Gastroenterol & Hepatol"},{"key":"10.5604\/16652681.1231577_bib0090","doi-asserted-by":"crossref","first-page":"e40959","DOI":"10.5812\/hepatmon.guideline","article-title":"Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline","volume":"16","author":"Alavian","year":"2016","journal-title":"Hepatitis Monthly"},{"key":"10.5604\/16652681.1231577_bib0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"The Lancet"},{"key":"10.5604\/16652681.1231577_bib0100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/16652681.1231577_bib0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/16652681.1231577_bib0110","series-title":"J Gastroenterol and Hepatol","article-title":"Ledipasvir\/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus","author":"Chuang","year":"2016"},{"key":"10.5604\/16652681.1231577_bib0115","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"New Engl J Med"},{"key":"10.5604\/16652681.1231577_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.5604\/16652681.1231577_bib0125","first-page":"92","article-title":"Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment","volume":"23","author":"Hill","year":"2015","journal-title":"Topics in Antiviral Medicine"},{"key":"10.5604\/16652681.1231577_bib0130","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.5604\/16652681.1231577_bib0135","doi-asserted-by":"crossref","first-page":"e41077","DOI":"10.5812\/hepatmon.41077","article-title":"Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis","volume":"16","author":"Alavian","year":"2016","journal-title":"Hepatitis Monthly"},{"key":"10.5604\/16652681.1231577_bib0140","first-page":"205","article-title":"Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients","volume":"27","author":"Kahveci","year":"2016","journal-title":"Turk J Gas-troenterol. (the Official Journal of Turkish Society of Gastroenterology)"},{"key":"10.5604\/16652681.1231577_bib0145","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1473-3099(16)30264-X","article-title":"The Middle East and hepatitis C virus infection: does it need special attention?","volume":"16","author":"Alavian","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.5604\/16652681.1231577_bib0150","series-title":"Hepatitis Monthly","article-title":"Next Steps for Eradication of Hepatitis C in the Era of Direct Acting Antivirals","author":"Hesamizadeh","year":"2014"},{"key":"10.5604\/16652681.1231577_bib0155","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New Engl J Med"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publisherspanel.com\/icid\/pdf\/1231577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:35:43Z","timestamp":1761647743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1665268119303813"],"URL":"https:\/\/doi.org\/10.5604\/16652681.1231577","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/16652681.1231577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}